« Previous
Next »
Maturitas
Volume 57, Issue 1
, Pages 39-41
, 20 May 2007
Primary prevention of breast cancer: New approaches
References
- Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA. 2003;290(10):1331–1336
- . Adult Weight Change and Risk of Postmenopausal Breast Cancer 10.1001/jama.296.2.193. JAMA. 2006;296(2):193–201
- Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA. 1998;279(7):535–540
- Folate intake, alcohol and risk of breast cancer among postmenopausal women in Denmark. Eur J Clin Nutr. 2006;60(2):280–286
- . Does dietary folate intake modify effect of alcohol consumption on breast cancer risk? Prospective cohort study. BMJ. 2005;331(7520):807
- Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295(6):629–642
- Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA. 2001;285(6):769–776
- Intake of fruits, vegetables and selected micronutrients in relation to the risk of breast cancer. Int J Cancer. 2003;105(3):413–418
- Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000
- Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–137
- The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281(23):2189–2197
- Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–2741
- Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637–645
- . Aromatase inhibitors in breast cancer. N Engl J Med. 2003;(24):2431–2442
- . Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst. 2006;98(18):1285–1291
- . Long-term effects of aromatase inhibitors on bone. J Steroid Biochem Mol Biol. 2005;95(1–5):151–154
- . Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358–366
- Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol. 2005;6(10):798–808
- . Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159–1169
- Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98(17):1204–1214
- US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002;137(6):526–8.
PII: S0378-5122(07)00070-9
doi: 10.1016/j.maturitas.2007.02.010
© 2007 Elsevier Ireland Ltd. All rights reserved.
« Previous
Next »
Maturitas
Volume 57, Issue 1
, Pages 39-41
, 20 May 2007
